ロード中...
Development of a physiologically based pharmacokinetic model for intravenous lenalidomide in mice
PURPOSE: Lenalidomide is used widely in B-cell malignancies for its immunomodulatory activity. It is primarily eliminated via the kidneys, with a significant proportion of renal elimination attributed to active processes. Lenalidomide is a weak substrate of P-glycoprotein (P-gp), though it is unclea...
保存先:
| 出版年: | Cancer Chemother Pharmacol |
|---|---|
| 主要な著者: | , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
2019
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7375688/ https://ncbi.nlm.nih.gov/pubmed/31493176 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00280-019-03941-z |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|